Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440

Inclusion Criteria: * At least 18 years of age * In female subjects either childbearing potential terminated by surgery or one year post-menopausal, or a negative serum pregnancy test during screening and the willingness not to become pregnant during the study period and 30 days after the last vaccination by practicing reliable methods of contraception * Written informed consent obtained prior to study entry Exclusion Criteria: * History of clinical manifestation of any flavivirus infection * History of vaccination against Japanese encephalitis (JE), Yellow fever and Dengue fever (an anti-JEV neutralizing antibody titer \>= 1:10 at baseline is acceptable for inclusion, these subjects will be part of the safety population, but will not be analyzed for immunogenicity in the per-protocol analysis) * History of any previous Hepatitis A vaccination and infection * Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine * Planned administration of another vaccine during the study period * Immunodeficiency including post-organ-transplantation or immunosuppressive therapy * A family history of congenital or hereditary immunodeficiency * History of autoimmune disease * Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within six months of vaccination. * Any acute infections within 4 weeks prior to enrollment * Infection with human immunodeficiency virus (HIV), Hepatitis B (HBsAg) or Hepatitis C